TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34130758

Group type: EXPERIMENTAL
Intervention: OUD-CDS intervention (access to clinical decision support tool)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (care as usual)
Number of subjects: 55
Study: 32406431

Group type: EXPERIMENTAL
Intervention: Vitamin A (2000 IU d‐1)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Vitamin D (400 IU d‐1)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Combination of Vitamin A (2000 IU d‐1) and D (400 IU d‐1)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Standard pulmonary tuberculosis therapy alone
Number of subjects: 800
Study: 35944371

Group type: EXPERIMENTAL
Intervention: dTMS twice a day during 2 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: dTMS twice a day during 3 weeks
Number of subjects: 32
Study: 34134834

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Panic-Focused Psychodynamic Psychotherapy (PFPP)
Number of subjects: 161
Study: 32725073

Group type: EXPERIMENTAL
Intervention: Liberal fluid therapy (1500 ml of lactated Ringer's)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Restrictive fluid therapy (250 ml of lactated Ringer's)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Liberal fluid therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Restrictive fluid therapy
Number of subjects: 46
Study: 35349019

Group type: EXPERIMENTAL
Intervention: COVID-19 impact on research engagement
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: COVID-19 impact on lives
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Suggestions for research engagement during COVID-19
Number of subjects: 15
Study: 34496928

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Suanzaoren decoction (SZRD)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) combined with Suanzaoren decoction (SZRD)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 240
Study: 35440333

Group type: EXPERIMENTAL
Intervention: Evening primrose vaginal capsule (500 mg) used vaginally, with a second capsule administered two hours later.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo used in the control group.
Number of subjects: 100
Study: 32965787

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 35436876

Group type: EXPERIMENTAL
Intervention: Peer education based on Pender’s health promotion model
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study: 33910851

Group type: EXPERIMENTAL
Intervention: LOCalizerTM and intraoperative ultrasound (IOUS)
Number of subjects: 5
Study: 32664995

Group type: EXPERIMENTAL
Intervention: glasdegib + LDAC
Number of subjects: 116

Group type: COMPARATOR
Intervention: LDAC
Number of subjects: 116
Study: 36317276

Group type: EXPERIMENTAL
Intervention: Arthritis gloves
Number of subjects: 206

Group type: COMPARATOR
Intervention: Loose‐fitting gloves (control)
Number of subjects: 206
Study: 34214823

Group type: EXPERIMENTAL
Intervention: Multiple exemplar extinction (CSs and two novel dog images similar to the CS+)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Standard extinction control (matched for number of CS+ and CS- presentations)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Extended extinction control (matched for total number of extinction trials)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Other stimuli extinction control (CSs and two novel stimuli unrelated to the CS+)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Multiple exemplar extinction
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Multiple, Extended, and Other stimuli groups
Number of subjects: 134
Study: 33071982

Group type: EXPERIMENTAL
Intervention: FABP4
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: FABP5
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Estimated glomerular filtration rate
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Triglycerides
Number of subjects: 256
Study: 35384909

Group type: EXPERIMENTAL
Intervention: nitrendipine + captopril
Number of subjects: 3756

Group type: EXPERIMENTAL
Intervention: nitrendipine + spironolactone hydrochlorothiazide + captopril
Number of subjects: 3756

Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide + spironolactone
Number of subjects: 3756
Study: 34600602

Group type: EXPERIMENTAL
Intervention: Apalutamide 240 mg once daily plus abiraterone acetate 1000 mg once daily and prednisone 5 mg twice daily
Number of subjects: 982

Group type: COMPARATOR
Intervention: Placebo plus abiraterone acetate and prednisone
Number of subjects: 982

Group type: EXPERIMENTAL
Intervention: Apalutamide plus abiraterone-prednisone
Number of subjects: 982

Group type: COMPARATOR
Intervention: Abiraterone-prednisone
Number of subjects: 982
Study: 36423214

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study: 33992229

Group type: EXPERIMENTAL
Intervention: High frequency transcutaneous electrical nerve stimulation (TENS) at root level
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 140
Study: 32293236

Group type: EXPERIMENTAL
Intervention: Single Take Charge session (TC1, n=132)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Two Take Charge sessions (TC2, n=138)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Take Charge intervention (TC1 + TC2)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control intervention (n=130)
Number of subjects: 400
Study: 35787704

Group type: COMPARATOR
Intervention: Canagliflozin treatment
Number of subjects: 10142

Group type: EXPERIMENTAL
Intervention: Liver function tests (ALT, AST, γGT, ALP)
Number of subjects: 10142

Group type: EXPERIMENTAL
Intervention: γGT levels
Number of subjects: 10142

Group type: EXPERIMENTAL
Intervention: ALT levels
Number of subjects: 10142
Study: 34791068

Group type: EXPERIMENTAL
Intervention: Fluorine‐18 fluorodeoxyglucose (18F‐FDG) PET-CT scanning (FDG‐PET) before tapering (baseline) and after maximal tapering.
Number of subjects: 79
Study: 32276809

Group type: EXPERIMENTAL
Intervention: HeartMate 3 (HM3)
Number of subjects: 1020

Group type: COMPARATOR
Intervention: HeartMate II (HMII)
Number of subjects: 1020
Study: 34785078

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 0
Study: 32601973

Group type: EXPERIMENTAL
Intervention: 1200 mg NAC twice daily (high dose group)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 1200 mg NAC daily (low dose group)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Paclitaxel only (control group)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 1200 mg NAC twice daily (high dose group) and 1200 mg NAC daily (low dose group)
Number of subjects: 75
Study: 34779905

Group type: EXPERIMENTAL
Intervention: Non-replacement side (0.019 × 0.025-inch SS)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Replacement side (new archwire each visit)
Number of subjects: 28
Study: 33782334

Group type: EXPERIMENTAL
Intervention: Repeat surgery
Number of subjects: 37

Group type: COMPARATOR
Intervention: Other nonsurgical management
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 37

Group type: COMPARATOR
Intervention: Neurosurgeons with neuro-oncology fellowship training
Number of subjects: 37

Group type: COMPARATOR
Intervention: Neurosurgeons without neuro-oncology fellowship training
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Randomized trial participation
Number of subjects: 37
Study: 33830898

Group type: EXPERIMENTAL
Intervention: Micro-fragmented adipose tissue (MFAT) injections under ultrasound guidance
Number of subjects: 10
Study: 32818641

Group type: EXPERIMENTAL
Intervention: Bleaching gel activated with 915 nm diode laser (1.5 W)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Bleaching gel activated with 915 nm diode laser (2.5 W)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Bleaching gel activated with 445 nm diode laser (1 W)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Bleaching gel activated with 445 nm diode laser (1.5 W)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Bleaching gel without laser activation (control group)
Number of subjects: 65
Study: 35133415

Group type: EXPERIMENTAL
Intervention: 5 mg tirzepatide
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: 10 mg tirzepatide
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: 15 mg tirzepatide
Number of subjects: 475

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 475
Study: 32888944

Group type: EXPERIMENTAL
Intervention: Integration of baseline clinical and microRNA variables
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical variables alone
Number of subjects: 0
Study: 32991458

Group type: EXPERIMENTAL
Intervention: NutriAct dietary pattern with high unsaturated fat, plant proteins, and fibres
Number of subjects: 502

Group type: COMPARATOR
Intervention: Usual care and dietary recommendations according to the German Nutrition Society (DGE)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: NutriAct dietary pattern
Number of subjects: 502
Study: 35778473

Group type: EXPERIMENTAL
Intervention: Directly coated HIV-1 SOSIP ELISAs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antibody-immobilized ELISAs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomly biotinylated Env-coated ELISAs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All antigen immobilization methods
Number of subjects: 0
Study: 33892641

Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg/month (240 mg loading dose)
Number of subjects: 462

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462
Study: 34323688

Group type: EXPERIMENTAL
Intervention: Home T2PSG
Number of subjects: 128

Group type: COMPARATOR
Intervention: Simultaneous T1PSG and T2PSG
Number of subjects: 128
Study: 34503985

Group type: EXPERIMENTAL
Intervention: Navafenterol 600 µg via inhalation
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol (UMEC/VI) 62.5 µg/25 µg
Number of subjects: 73

Group type: COMPARATOR
Intervention: Navafenterol and UMEC/VI
Number of subjects: 73
Study: 32977348

Group type: COMPARATOR
Intervention: Pharmacotherapy (placebo-controlled trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine airway clearance and treatment of recurrent respiratory tract infections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Organ-specific treatment for non-respiratory symptoms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participation in patient registries
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Knowledge of genotype-specific course of the disease
Number of subjects: 0
Study: 32127889

Group type: EXPERIMENTAL
Intervention: Intra-operative low-dose ketamine (0.15mg/kg bolus at induction and continuous infusion of 0.12 mg/kg/hour till start of skin closure)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups received Morphine 0.1 mg/kg IV at debulking
Number of subjects: 46
Study: 35995357

Group type: EXPERIMENTAL
Intervention: Combined external ventricular drainage and endoscope‐assisted microsurgery
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 41
Study: 33315503

Group type: COMPARATOR
Intervention: Fat graft injections
Number of subjects: 45

Group type: COMPARATOR
Intervention: Nanofat-enriched fat graft injections
Number of subjects: 45
Study: 32447857

Group type: EXPERIMENTAL
Intervention: Acupuncture plus hyperbaric oxygen (HBO) therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (simple HBO therapy)
Number of subjects: 28
Study: 35993176

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 1158

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1158
Study: 34473822

Group type: EXPERIMENTAL
Intervention: Interventional bundle (A: sporicidal cleaning, B: probiotics, C: improvement in personal hygiene)
Number of subjects: 25311

Group type: COMPARATOR
Intervention: Individual interventions (A, B, C)
Number of subjects: 25311
Study: 36056784

Group type: EXPERIMENTAL
Intervention: Intralesional purified protein derivative (PPD) injected at a dose of 0.1 ml every 2 weeks until complete improvement or for a maximum of four sessions.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intralesional Candida antigen (CA) injected at a dose of 0.1 ml every 2 weeks until complete improvement or for a maximum of four sessions.
Number of subjects: 80
Study: 33492782

Group type: EXPERIMENTAL
Intervention: EBP education (experimental group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Self-directed EBP education (control group)
Number of subjects: 80
Study: 35364051

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine sternal block
Number of subjects: 52

Group type: COMPARATOR
Intervention: Normal saline injection
Number of subjects: 52
Study: 36155998

Group type: COMPARATOR
Intervention: Radiofrequency ozone therapy
Number of subjects: 153

Group type: COMPARATOR
Intervention: Injection of anti‐inflammatory analgesic solution into the internal orifice of nerve root
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine hook operation (in addition to basic group treatment)
Number of subjects: 153
Study: 34036813

Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus auricular acupressure treatment twice weekly for 6 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus auricular acupressure treatment
Number of subjects: 30
Study: 33175623

Group type: EXPERIMENTAL
Intervention: Nanocolloidal silver-based gel (SilvoGel)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Eosin 2% solution
Number of subjects: 32
Study: 35262716

Group type: EXPERIMENTAL
Intervention: Multidisciplinary prehabilitation (4 supervised sessions, 2 sessions per week for at least 2 months before TKR)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Usual care (information booklet and standard advice by the orthopedic surgeon)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Multidisciplinary prehabilitation
Number of subjects: 262

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 262
Study: 32508281

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Number of subjects: 0
Study: 32788154

Group type: EXPERIMENTAL
Intervention: ConnEDCt mobile EDC framework for iOS devices and personal computers
Number of subjects: 0
Study: 35587267

Group type: EXPERIMENTAL
Intervention: Two mimotopes synthesized as mimotopes of dopamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selegiline (commercial inhibitor of MAO-B)
Number of subjects: 0
Study: 34247040

Group type: EXPERIMENTAL
Intervention: Wine group (27 g of alcohol per day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethanol group (27 g of alcohol per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No alcohol group
Number of subjects: 0
Study: 35051648

Group type: EXPERIMENTAL
Intervention: Low FODMAP-gluten-free diet
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual gluten-free diet
Number of subjects: 70
Study: 34516591

Group type: EXPERIMENTAL
Intervention: Positive verbalization (PV)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Negative verbalization (NV)
Number of subjects: 73
Study: 34997314

Group type: EXPERIMENTAL
Intervention: Intravenous placebo + oral cetirizine 10 mg
Number of subjects: 37

Group type: COMPARATOR
Intervention: Intravenous diphenhydramine 50 mg + oral placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 37
Study: 34318757

Group type: EXPERIMENTAL
Intervention: Standard-dose CT (120 kV and 300 mA)
Number of subjects: 740

Group type: COMPARATOR
Intervention: Low-dose CT (80 kV and 40 mA)
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Standard-dose CT
Number of subjects: 740

Group type: COMPARATOR
Intervention: Low-dose CT
Number of subjects: 740
Study: 32170307

Group type: EXPERIMENTAL
Intervention: CBT-I followed by PAP
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: CBT-I concurrent with PAP
Number of subjects: 121

Group type: COMPARATOR
Intervention: PAP only
Number of subjects: 121
Study: 35642330

Group type: EXPERIMENTAL
Intervention: Vaccinated individuals
Number of subjects: 60632

Group type: COMPARATOR
Intervention: Unvaccinated individuals
Number of subjects: 60632

Group type: COMPARATOR
Intervention: Unvaccinated seropositive individuals
Number of subjects: 60632
Study: 34530316

Group type: EXPERIMENTAL
Intervention: VOICES (n = 51)
Number of subjects: 113

Group type: COMPARATOR
Intervention: GirlHealth (attention control; n = 62)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Both conditions
Number of subjects: 113
Study: 35240285

Group type: EXPERIMENTAL
Intervention: Anterior-Posterior Axis Line (APAL)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Transepicondylar Axis Line (TEAL)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: APAL
Number of subjects: 32

Group type: COMPARATOR
Intervention: TEAL
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: APAL and TEAL
Number of subjects: 32
Study: 32283195

Group type: COMPARATOR
Intervention: Oleogel-dissolved CoQ10 (1 g CoQ10/5 g oleogel-disk)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oleogel-dissolved CoQ10 (repeated-dose for 14 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oleogel-dissolved CoQ10
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (solid form of CoQ10)
Number of subjects: 0
Study: 36346322

Group type: EXPERIMENTAL
Intervention: Spectrum Red (2.5 mg THC, 0.3 mg CBD/softgel)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Spectrum Yellow (0.9 mg THC, 20 mg CBD/mL of oil)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 33572499

Group type: EXPERIMENTAL
Intervention: HIIT (High-Intensity Interval Training) - 6 weeks, 12 bouts first 2 weeks, 16 bouts in weeks 3 and 4, and 20 bouts in the last two weeks x 30‐s intervals interspersed with 1‐min rest periods, performed thrice weekly
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 19
Study: 32318695

Group type: EXPERIMENTAL
Intervention: Allopurinol 600 mg once daily for 20 weeks
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 36084047

Group type: EXPERIMENTAL
Intervention: 24-month multi-component health promotion programme based on educational and motivational strategies
Number of subjects: 288

Group type: COMPARATOR
Intervention: Basic educational strategy (control group)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: 24-month multi-component health promotion programme
Number of subjects: 288
Study: 33248975

Group type: EXPERIMENTAL
Intervention: 5 mg/kg intravenous tranexamic acid
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10 mg/kg intravenous tranexamic acid
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 15 mg/kg intravenous tranexamic acid
Number of subjects: 30
Study: 35414602

Group type: EXPERIMENTAL
Intervention: Intensive glucose treatment (serum glucose <110 mg/dL)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Standard treatment (serum glucose <180 mg/dL)
Number of subjects: 146
Study: 32599647

Group type: EXPERIMENTAL
Intervention: Wide local excision (WLE)
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Mohs micrographic surgery (MMS)
Number of subjects: 547

Group type: COMPARATOR
Intervention: WLE
Number of subjects: 547

Group type: COMPARATOR
Intervention: MMS
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Overall surgical management
Number of subjects: 547
Study: 32429680

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Pharmacological treatment (diclofenac sodium)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) and pharmacological treatment (diclofenac sodium)
Number of subjects: 2
Study: 34358953

Group type: EXPERIMENTAL
Intervention: High g1 treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard g1 treatment
Number of subjects: 40
Study: 32181830

Group type: EXPERIMENTAL
Intervention: Nonaerosol spray sunscreen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 35766288

Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) intervention with four home visits over 1 year
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) intervention
Number of subjects: 420
Study: 33590999

Group type: EXPERIMENTAL
Intervention: Preintubation noninvasive ventilation
Number of subjects: 2427
Study: 33067280

Group type: EXPERIMENTAL
Intervention: Initiation of mental healthcare (psychometric testing by GP, talk therapy by GP, contact with a psychologist, contact with a psychiatrist, psychotropic medication)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Less impaired mental health
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Socioeconomic factors
Number of subjects: 350
Study: 35678328

Group type: EXPERIMENTAL
Intervention: Panitumumab-based maintenance regimens after FOLFOX/panitumumab induction
Number of subjects: 229
Study: 34206058

Group type: EXPERIMENTAL
Intervention: Hepatitis B birth dose vaccine (HepB‐BD) administered to infants in addition to routine vaccines (0-8-12-16 weeks) during the intervention period.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional immunization schedule (8-12-16 weeks) during the control period.
Number of subjects: 24
Study: 36377268

Group type: EXPERIMENTAL
Intervention: Pecha Kucha method training via smartphones
Number of subjects: 70

Group type: COMPARATOR
Intervention: Classical verbal instruction method
Number of subjects: 70
Study: 34142748

Group type: EXPERIMENTAL
Intervention: Transdiagnostic cognitive-behavior therapy (tCBT)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 191
Study: 32392091

Group type: EXPERIMENTAL
Intervention: Self-Reported Stuttering Severity (SRSS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Percentage Syllables Stuttered (%SS)
Number of subjects: 0
Study: 34799999

Group type: EXPERIMENTAL
Intervention: Parent‐mediated intervention (adapted responsive teaching; ART)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Referral to early intervention and monitoring (REIM)
Number of subjects: 0